Reach further, in an Open Access Journal Endocrinology, Diabetes & Metabolism Case Reports

ISSN 1470-3947 (print)
ISSN 1479-6848 (online)

Searchable abstracts of presentations at key conferences in endocrinology

Published by BioScientifica
Endocrine Abstracts (2010) 22 P541 

The effect of undecanoat testosterone depot on the prostate volume

Dan Peretianu1, Mara Carsote2, Alexandrina Clodeanu1, Dana Cristina Staicu1, Corina Chirita3, Cristina Ene3, Valentin Radoi2 & Catalina Poiana2,3

Author affiliations

Introduction: Testosterone therapy in elderly is controversial, because of the effect on prostate. The old age itself is not a contraindication in the therapy of hypogonadism.

Aim: We analyze the effect of 24 months of therapy with testosterone undecanoat depot (1000 mg/4 ml) (TUD) on the volume of the prostate (VP).

Patients and method: The patients were 79 symptomatic hypogonadic men, with normal value of PSA (<4 g/l). The urologic consult detected no prostate cancer. No contraindication of testosterone therapy was diagnosed. VP was appreciated by per-abdominal ultrasound, with a probe of 3.5 MHz, expressed by elliptical volume (cm3). The statistics analyze was performed by Student’s t-test.

Results: The patients were divided into seven groups according to their age (18–29, 30–39, 40–49, 50–59, 60–69, 70–79, and 80–89 years). The VP was measured at baseline and after14 days, 3, 6, 12, and respective 24 months of therapy. The initial VP increased with age, with statistically significant changes between the seven groups (P<0.5).

The differences between the variations of VP during TUD were analyzed for each group and then compared between them. For the first five younger groups there were no statistically significant differences, suggesting that correctly selected patients may continue the therapy for a long time. Statistically significant differences were found between the group 6 and all the others groups only at 14 days and 3 months of therapy, suggesting that for the patients aged between 70 and 79 years, after an initial increase, the VP had no major changes for 24 months. The only different phenotype was found in the oldest group, where statistically significant differences were found at every evaluation.

Conclusions: The effect of TUD on the prostate is important to be analyzed, providing data that assure safety during a long time treatment.

This Issue/Conference

Article tools

My recently viewed abstracts

My recent searches